Figure 2. Top 5 Treatment Regimens at 1L (A and B) and 2L (C and D).

More than 5 regimens are presented for the calculation for the dMMR/MSI-H subgroup in panel D. This is due to the equal percentage of patients treated with doxorubicin pegylated liposomal and megestrol (joint fourth regimens) and everolimus plus letrozole and megestrol plus tamoxifen (joint fifth regimens).

Abbreviations: 1L, first-line; 2L, second-line; dMMR, mismatch repair deficient; LOT, line of therapy; MSI-H; microsatellite instability-high.